HomeCompareAVCNF vs EQR

AVCNF vs EQR: Dividend Comparison 2026

AVCNF yields 1666.67% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVCNF wins by $1839785666.22M in total portfolio value
10 years
AVCNF
AVCNF
● Live price
1666.67%
Share price
$0.12
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1839785666.26M
Annual income
$1,645,561,548,268,653.00
Full AVCNF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — AVCNF vs EQR

📍 AVCNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVCNFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVCNF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVCNF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVCNF
Annual income on $10K today (after 15% tax)
$141,666.67/yr
After 10yr DRIP, annual income (after tax)
$1,398,727,316,028,355.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, AVCNF beats the other by $1,398,727,316,025,108.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVCNF + EQR for your $10,000?

AVCNF: 50%EQR: 50%
100% EQR50/50100% AVCNF
Portfolio after 10yr
$919892833.15M
Annual income
$822,780,774,136,236.20/yr
Blended yield
89.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

AVCNF
No analyst data
Altman Z
-4.8
Piotroski
3/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVCNF buys
0
EQR buys
0
No recent congressional trades found for AVCNF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVCNFEQR
Forward yield1666.67%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$1839785666.26M$40.5K
Annual income after 10y$1,645,561,548,268,653.00$3,819.61
Total dividends collected$1825787439.21M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: AVCNF vs EQR ($10,000, DRIP)

YearAVCNF PortfolioAVCNF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$177,367$166,666.67$11,248$547.57+$166.1KAVCNF
2$2,952,503$2,762,720.66$12,701$666.53+$2.94MAVCNF
3$46,139,686$42,980,507.73$14,405$814.59+$46.13MAVCNF
4$677,098,258$627,728,794.51$16,413$999.84+$677.08MAVCNF
5$9,333,745,461$8,609,250,324.41$18,795$1,232.92+$9333.73MAVCNF
6$120,900,966,251$110,913,858,608.07$21,639$1,527.95+$120900.94MAVCNF
7$1,472,054,345,780$1,342,690,311,890.92$25,057$1,903.80+$1472054.32MAVCNF
8$16,853,789,214,559$15,278,691,064,574.45$29,197$2,385.87+$16853789.19MAVCNF
9$181,517,867,281,133$163,484,312,821,554.84$34,250$3,008.70+$181517867.25MAVCNF
10$1,839,785,666,259,465$1,645,561,548,268,653.00$40,467$3,819.61+$1839785666.22MAVCNF

AVCNF vs EQR: Complete Analysis 2026

AVCNFStock

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.

Full AVCNF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this AVCNF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVCNF vs SCHDAVCNF vs JEPIAVCNF vs OAVCNF vs KOAVCNF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.